

David Budd | Chief Executive Officer

Presentation has been modified from original use to remove competitor names

### **GENEDRIVE – AIM:GDR**




# Genedrive®: the Point-of-Need, molecular diagnostic gene reader

- We develop highly accurate molecular diagnostic assays for use on our Genedrive® instrument
- PCR is the base chemistry
- Rapid results in as little as 27 minutes
- **Single use**, disposable reagent cartridge revenue model
- **Same instrument** platform is used across a range of applications
- **Low cost** <£500 unit, <£5-8 tests
- Customer price/test £15-£80



### **GENEDRIVE – COMMERCIAL STAGE COMPANY**





# Genedrive<sup>®</sup> 96 SARS-CoV-2 Kit

genedrive






## **Genedrive<sup>®</sup> 96 SARS-CoV-2 Kit**

# Innovative PCR to meet the need for increased consistency, throughput, and ease of use in COVID-19 PCR


- A Unique, one-step CE-IVD PCR assay designed to detect SARS-CoV-2 infection
- Single PCR solid bead format eliminates the need for time-consuming, error prone reagent preparation
- Streamlines the laboratory workflow and allows for high volume throughput.
- Room temperature stability to access a global market
- £8-£10 / test (x96), circa 60% GM, manufacturing capacity with Cytiva 10,000 test / hour







### Simple '1-step' Test





### **Performance Characteristics**

#### Performance study data


180 clinical specimens, collected using various swab types (BD, Copan, Sterilab) and extraction kits/methods.

Metric	Result (%)	95% Confidence Interval (%)
Sensitivity	100.0%	97.0 - 100.0
Specificity	98.2%	90.4 - 99.9
Diagnostic Accuracy	99.4%	96.9 - 99.7
PPV	99.2%	95.6 - 100.0
NPV	100.0%	93.4 - 100.0

Limit of Detection =  $0.5 \text{ copies/}\mu\text{I}$  (10 copies per reaction)



### **Sample Comparison Workflow Summaries**





## **Competitor Comparison**


	genedrive	Comp A	Comp C	Comp D	Comp B	Comp E	Comp F
Test Name				ļ	· · · · · · · · · · · · · · · · · · ·	;······;	
Ambient shipping/storage	Yes	Yes	No	No	No	No	Yes
Multiple Gene Targets	Yes	Yes	No	Yes	Yes	Yes	?
Human RNA control	Yes	No	No	No	No	No	No
Operator interactions	4	6	6	6	6	6	6
Pipetting steps	1	2	3	2	3	3	1

.....



### A Global Market

WHO chief Tedros Adhanom warned on Tuesday against complacency ""Although the situation in Europe is improving, globally it is worsening".





<b>Current / Distribution Agreements</b>	Regulatory status
<b>Europe:</b> Austria, Germany, United Kingdom, Switzerland, Turkey, Spain, Portugal, Belgium, The Netherlands, Luxembourg, Poland, Hungary, Czech Republic, Slovakia, Sweden, Norway, Denmark, France, Cyprus <b>Central East Europe:</b> Romania, Slovenia, Croatia, Ukraine, Estonia, Lithuania, Latvia, Moldova, Albania, Bulgaria, Serbia, Bosnia and Hercegovina, Montenegro	CE Mark 22 May
<b>Africa:</b> Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Congo, Democratic Republic of Congo, Cote d'Ivoire, Egypt, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Lesotho, Liberia, Libya, Madagascar, Malawi, Mali, Morocco, Mozambique, Namibia, Niger, Nigeria, Rwanda, Senegal, Seychelles, Sierra Leone, South Africa, South Sudan,	WHO EUA Applied + Country Specific
Sudan, Swaziland, Togo, Tunisia, Uganda, Zambia, Zimbabwe. <b>Middle East:</b> Iran, Iraq, Saud Arabia, Yemen, Syria, United Arab Emirates, Israel, Jordan, Palestine, Lebanon, Oman, Kuwait, Qatar, Armenia, Bahrain, Turkey, Azerbaijan, Uzbekistan Tajikistan, Turkmenistan, Kyrgyzstan, Kosovo, Kazakhstan India	Country Specific

#### **Desired Distribution Channels -**

USA	FDA EUA Applied
South America	
Mexico	Country Specific



## **Genedrive 96 SARS-CoV-2 Summary**

#### Huge market potential and currently limited price sensitivity

- Unique product design with meaningful, valuable benefits to the user
- Top tier clinical performance specifications
- Temperature stable nature facilitates global distribution to global markets
- Competitive pricing with attractive margins
- Commercial scale manufacturing capability with Cytiva
- Distribution routes established and even more being established
- CE Marking achieved, additional registrations in process
- Global pandemic continues to grow, making global distribution capability important
- COVID-19 can only be controlled through constant monitoring (testing), social distancing, and treatment (vaccine)
- Company anticipates recording first sales this month.



# **Antibiotic Induced Hearing Loss**

#### **Genedrive<sup>®</sup> MT-RNR1 ID Kit**

### **First to Market Global Opportunity**



## First to market opportunity


- Percentage of children (1/500) will suffer permanent deafness when given the drug gentamycin.
- Given within 1 hour of admission to Neonatal Intensive Care.
- Caused by a genetic mutation called MT-RNR1.
- Use Genedrive test to give a rapid (27 min) genetic result in the NICU ward.
- Give alternative antibiotics which are readily available.
- Genedrive is the first company in the world to develop a genetic test for rapid testing of this sort.







### **Genedrive Workflow**







## **Clear Benefits in Health and in Cost**

#### **UK Example**

- The current hospital tests used take 2-5 days for a result, therefore they are unsuitable for emergency care
- The test provides a clear patient benefit by helping to prevent antibiotic related hearing loss in neonates
- In the UK there are approx. 90,000 babies admitted to neonatal intensive care each year
- Therefore our test has the potential to save approx. 180 babies each year in the UK from going deaf
- Health economic case is positive vs. the need for expensive clinical interventions, including bilateral cochlear implants







## Market Opportunity

- Approx 90,000 babies admitted each year to NICU in the UK
- Assume 'Western World" market opportunity 1.25M tests / year
- Test economics <£10 to make, £35 to distributors, £50-£85 direct depending on reimbursement / country
- Approx 1:500 carry the mutation (Preliminary UK Biobank study of 500,000 individuals)
- Based on this mutation frequency approx. 2500-3000 babies could be prevented from going deaf every year in EU/USA
- Global market value estimated at £40-£65M per year depending on route to market.



### **Clinical Performance**

#### Diagnostic accuracy of Genedrive MT-RNR1 ID Kit

Index Test		Detected	Not detected	
	Detected	59	0	
	Not detected	0	244	

**Reference Test** 


- Sensitivity = 100% (93.9% to 100% CI)
- Specificity = 100% (98.5% to 100% Cl)



## **Genedrive AIHL Summary**

- World first product design with health economic benefits
- Clinical performance specifications match best in class lab testing
- Temperature stable cartridges contract manufactured by Cytiva
- Competitive pricing with attractive margins
- Launching autumn 2020 with scalable Distributor contracted
- CE Marking achieved







# for more information.